The stock of Iovance Biotherapeutics Inc (IOVA) has seen a 4.88% increase in the past week, with a -23.60% drop in the past month, and a -41.34% decrease in the past quarter. The volatility ratio for the week is 8.75%, and the volatility levels for the past 30 days are at 6.58% for IOVA. The simple moving average for the last 20 days is -10.89% for IOVA stock, with a simple moving average of -7.19% for the last 200 days.
Is It Worth Investing in Iovance Biotherapeutics Inc (NASDAQ: IOVA) Right Now?
Additionally, the 36-month beta value for IOVA is 0.64. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IOVA is 223.70M and currently, short sellers hold a 22.34% ratio of that float. The average trading volume of IOVA on June 17, 2024 was 5.92M shares.
IOVA) stock’s latest price update
The stock price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) has plunged by -3.20 when compared to previous closing price of 8.43, but the company has seen a 4.88% gain in its stock price over the last five trading sessions. fool.com reported 2024-06-10 that Iovance Biotherapeutics makes a cell therapy called Amtagvi for melanoma. Amtagvi isn’t currently approved as a first-line treatment.
Analysts’ Opinion of IOVA
Many brokerage firms have already submitted their reports for IOVA stocks, with Goldman repeating the rating for IOVA by listing it as a “Buy.” The predicted price for IOVA in the upcoming period, according to Goldman is $12 based on the research report published on November 20, 2023 of the previous year 2023.
Barclays, on the other hand, stated in their research note that they expect to see IOVA reach a price target of $18, previously predicting the price at $40. The rating they have provided for IOVA stocks is “Overweight” according to the report published on September 18th, 2023.
Wells Fargo gave a rating of “Overweight” to IOVA, setting the target price at $17 in the report published on May 30th of the previous year.
IOVA Trading at -26.11% from the 50-Day Moving Average
After a stumble in the market that brought IOVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.48% of loss for the given period.
Volatility was left at 6.58%, however, over the last 30 days, the volatility rate increased by 8.75%, as shares sank -21.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.00% lower at present.
During the last 5 trading sessions, IOVA rose by +4.88%, which changed the moving average for the period of 200-days by +33.33% in comparison to the 20-day moving average, which settled at $9.04. In addition, Iovance Biotherapeutics Inc saw 0.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IOVA starting from Rothbaum Wayne P., who purchase 5,000,000 shares at the price of $9.15 back on Feb 20 ’24. After this action, Rothbaum Wayne P. now owns 28,067,333 shares of Iovance Biotherapeutics Inc, valued at $45,750,000 using the latest closing price.
MCPEAK MERRILL A, the Director of Iovance Biotherapeutics Inc, purchase 250,000 shares at $9.15 during a trade that took place back on Feb 20 ’24, which means that MCPEAK MERRILL A is holding 320,150 shares at $2,287,500 based on the most recent closing price.
Stock Fundamentals for IOVA
Current profitability levels for the company are sitting at:
- -245.5 for the present operating margin
- -16.33 for the gross margin
The net margin for Iovance Biotherapeutics Inc stands at -236.16. The total capital return value is set at -0.59. Equity return is now at value -66.77, with -53.07 for asset returns.
Based on Iovance Biotherapeutics Inc (IOVA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -31.82. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -134.09.
Currently, EBITDA for the company is -427.43 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 1173.12. The receivables turnover for the company is 8.14for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.63.
Conclusion
In conclusion, Iovance Biotherapeutics Inc (IOVA) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
